Aberrations in the epidermal growth factor receptor gene in 958 patients with diverse advanced tumors: Implications for therapy

Annals of Oncology

Volumn 24, Issue 3, 2013, Pages 838-842

  Wheler, J J ^a   Falchook, G S ^a   Tsimberidou, A M ^a   Hong, D S ^a   Naing, A ^a   Piha Paul, S A ^a   Chen, S S ^b   Fu, S ^a   Stephen, B ^a   Fok, J Y ^a   Janku, F ^a   Kurzrock, R ^a  

^a Clinical Trials Program   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

EGFR mutation; Non NSCLC; Phase I trials; Response; Time to treatment failure

Indexed keywords

CARBOPLATIN; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; PACLITAXEL;

ADRENAL CORTEX CARCINOMA; ADULT; ADVANCED CANCER; AGED; ARTICLE; BASAL CELL CARCINOMA; BILE DUCT CARCINOMA; BREAST CANCER; CANCER PATIENT; CARCINOID; DISEASE ACTIVITY; FEMALE; GENE MUTATION; HEAD AND NECK CANCER; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OVARY CANCER; PARATHYROID CARCINOMA; PATIENT REFERRAL; PRIORITY JOURNAL; RECEPTOR GENE; SALIVARY GLAND CANCER; SARCOMA; SKIN CANCER; SOLID TUMOR; SYSTEMIC THERAPY; THYMUS CANCER; TREATMENT RESPONSE;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; MUTATION; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TREATMENT OUTCOME;

EID: 84874564640     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds524     Document Type: Article

References (41)

1. Flaherty KT, Puzanov I, Kim KB et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010; 363(9): 809-819.
2. Shaw AT, Yeap BY, Solomon BJ et al. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol 2011; 12(11): 1004-1012.
3. Demetri GD, von Mehren M, Blanke CD et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002; 347 (7): 472-480.
4. Braiteh F, Kurzrock R. Uncommon tumors and exceptional therapies: paradox or paradigm? Mol Cancer Ther 2007; 6(4): 1175-1179.
5. Janku F, Tsimberidou AM, Garrido-Laguna I et al. PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors. Mol Cancer Ther 2011; 10(3): 558-565.
6. Druker BJ, Talpaz M, Resta DJ et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344(14): 1031-1037.
7. Garrido-Laguna I, Hidalgo M, Kurzrock R. The inverted pyramid of biomarkerdriven trials. Nat Rev Clin Oncol 2011; 8(9): 562-566.
8. Stewart DJ, Kurzrock R. Cancer: the road to Amiens. J Clin Oncol 2009; 27(3): 328-333.
9. Chintala L, Kurzrock R. Epidermal growth factor receptor mutation and diverse tumors: case report and concise literature review. Mol Oncol 2010; 4(4): 306-308.
10. Sharma SV, Bell DW, Settleman J et al. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 2007; 7(3): 169-181.
11. Lynch TJ, Bell DW, Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350(21): 2129-2139.
12. Riely GJ, Pao W, Pham D et al. Clinical course of patients with non-small-cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin Cancer Res 2006; 12(3 Pt 1): 839-844.
13. Kosaka T, Yatabe Y, Endoh H et al. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res 2004; 64(24): 8919-8923.
14. Mitsudomi T, Kosaka T, Endoh H et al. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol 2005; 23 (11): 2513-2520.
15. Jackman DM, Yeap BY, Sequist LV et al. Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in nonsmall cell lung cancer patients treated with gefitinib or erlotinib. Clin Cancer Res 2006; 12(13): 3908-3914.
16. Janku F, Garrido-Laguna I, Petruzelka LB et al. Novel therapeutic targets in nonsmall cell lung cancer. J Thorac Oncol 2011; 6(9): 1601-1612.
17. Okamoto I, Araki J, Suto R et al. EGFR mutation in gefitinib-responsive small-cell lung cancer. Ann Oncol 2006; 17(6): 1028-1029.
18. Gwak GY, Yoon JH, Shin CM et al. Detection of response-predicting mutations in the kinase domain of the epidermal growth factor receptor gene in cholangiocarcinomas. J Cancer Res Clin Oncol 2005; 131(10): 649-652.
19. Schilder RJ, Sill MW, Chen X et al. Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study. Clin Cancer Res 2005; 11(15): 5539-5548.
20. Barber TD, Vogelstein B, Kinzler KW et al. Somatic mutations of EGFR in colorectal cancers and glioblastomas. N Engl J Med 2004; 351(27): 2883.
21. Lee JW, Soung YH, Kim SY et al. Somatic mutations of EGFR gene in squamous cell carcinoma of the head and neck. Clin Cancer Res 2005; 11(8): 2879-2882.
22. Kwak EL, Jankowski J, Thayer SP et al. Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas. Clin Cancer Res 2006; 12(14 Pt 1): 4283-4287.
23. Cho KS, Lee JS, Cho NH et al. Gene amplification and mutation analysis of epidermal growth factor receptor in hormone refractory prostate cancer. Prostate 2008; 68(8): 803-808.
24. Dahse R, Kosmehl H. Detection of drug-sensitizing EGFR exon 19 deletion mutations in salivary gland carcinoma. Br J Cancer 2008; 99(1): 90-92.
25. Kotoula V, Sozopoulos E, Litsiou H et al. Mutational analysis of the BRAF, RAS and EGFR genes in human adrenocortical carcinomas. Endocr Relat Cancer 2009; 16(2): 565-572.
26. Longatto-Filho A, Pinheiro C, Martinho O et al. Molecular characterization of EGFR, PDGFRA and VEGFR2 in cervical adenosquamous carcinoma. BMC Cancer 2009; 9: 212.
27. Murugan AK, Dong J, Xie J et al. Uncommon GNAQ, MMP8, AKT3, EGFR, and PIK3R1 mutations in thyroid cancers. Endocr Pathol 2011; 22(2): 97-102.
28. Teng YH, Tan WJ, Thike AA et al. Mutations in the epidermal growth factor receptor (EGFR) gene in triple negative breast cancer: possible implications for targeted therapy. Breast Cancer Res 2011; 13(2): R35.
29. Uribe P, Gonzalez S. Epidermal growth factor receptor (EGFR) and squamous cell carcinoma of the skin: molecular bases for EGFR-targeted therapy. Pathol Res Pract 2011; 207(6): 337-342.
30. Falchook GS, Wheler JJ, Naing A et al. A phase I study of bevacizumab in combination with sunitinib, sorafenib, and erlotinib plus cetuximab, and trastuzumab plus lapatinib. J Clin Oncol 2010; 28(15s Suppl.) (Abstr 2512).
31. Fok J, Kurzrock R, Tsimberidou AM et al. An umbrella protocol for histologyindependent, phase I modular study based on EGFR mutation status: using erlotinib alone or in combination with cetuximab, bortezomib, or dasatinib to overcome resistance. J Clin Oncol 2011; 29(Suppl.) (Abstr 2536).
32. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92(3): 205-216.
33. Tsimberidou AM, Iskander NG, Hong DS et al. Personalized medicine in a phase I clinical trials program: The MD Anderson Cancer Center Initiative. J Clin Oncol 2011; 29(Suppl.) (Abstr CRA2500).
34. Chen RW, Gopal AK, Smith SE et al. Results from a pivotal phase II study of brentuximab vedotin (SGN-35) in patients with relapsed or refractory Hodgkin lymphoma (HL). J Clin Oncol 2011; 29(Suppl.) (Abstr 8031).
35. Younes A, Bartlett NL, Leonard JP et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 2010; 363(19): 1812-1821.
36. Janku F, Stewart DJ, Kurzrock R. Targeted therapy in non-small-cell lung cancer-is it becoming a reality? Nat Rev Clin Oncol 2010; 7(7): 401-414.
37. Sordella R, Bell DW, Haber DA et al. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 2004; 305(5687): 1163-1167.
38. Jiang J, Greulich H, Janne PA et al. Epidermal growth factor-independent transformation of Ba/F3 cells with cancer-derived epidermal growth factor receptor mutants induces gefitinib-sensitive cell cycle progression. Cancer Res 2005; 65(19): 8968-8974.
39. Bamford S, Dawson E, Forbes S et al. The COSMIC (catalogue of somatic mutations in cancer) database and website. Br J Cancer 2004; 91(2): 355-358.
40. Centeno I, Blay P, Santamaria I et al. Germ-line mutations in epidermal growth factor receptor (EGFR) are rare but may contribute to oncogenesis: a novel germline mutation in EGFR detected in a patient with lung adenocarcinoma. BMC Cancer 2011; 11: 172.
41. Ikeda K, Nomori H, Mori T et al. Novel germline mutation: EGFR V843I in patient with multiple lung adenocarcinomas and family members with lung cancer. Ann Thorac Surg 2008; 85(4): 1430-1432.